Business
Kymera Therapeutics Announces Late-Breaking Oral Presentation of KT-621 Phase 1b Data at the American Academy of Dermatology (AAD) Annual Meeting
WATERTOWN, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new
About this update from Kymera Therapeutics, Inc.
[{"type":"text","content":"WATERTOWN, Mass., March 10, 2026 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, today announced that data from its KT-621 BroADen Phase 1b clinical trial in patients with atopic dermatitis will be presented in a late-breaking oral session at the American Academy of Dermatology (AAD) 2026 Annual Meeting. The meeting will be held March 27-31, 2026, in Denver, CO. Kymera will also host a booth (#3551) in the congress exhibit hall. “We are honored to have our KT-621 BroADen Phase 1b data selected for a late-breaking oral presentation at AAD,” said Jared Gollob, MD, Chief Medical Officer, Kymera Therapeutics. “We look forward to engaging with the dermatology community at this important forum and sharing our work to develop novel oral medicines for patients living with chronic immuno-inflammatory diseases.” AAD 2026 Late-Breaking Presentation Details Abstract Title: Clinical Activity and Safety of KT-621, an Oral STAT6 Degrader, in Moderate-to-Severe Atopic Dermatitis: Phase 1b Trial ResultsSession Title: Late-Breaking Research: Session 1Session Type: Oral PresentationPresentation Date/Time: Saturday, March 28, 2026, 9:24 AM MTLocation: Bellco Theatre A copy of the presentation will be available in the Resource Library section of Kymera's website after the session. About KT-621 KT-621 is an investigational, first-in-class, once-daily oral degrader of STAT6, the specific transcription factor responsible for IL-4/IL-13 signaling and the central driver of Type 2 inflammation. KT-621 is currently being evaluated in parallel Phase 2b clinical trials in atopic dermatitis (BROADEN2) and asthma (BREADTH). By selectively targeting STAT6 for degradation, KT-621 has the potential to provide a novel oral approach for patients living with Type 2 inflammatory diseases, which affect more than 140 million people worldwide. About Kymera TherapeuticsKymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the fi...